Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Oncology insights

- PMLiVE

Study suggests simple blood test could spare brain cancer patients risky surgery

The TriNetra-Glio test isolates broken-free tumour cells from the circulating tumour in the blood

- PMLiVE

Bristol Myers Squibb’s subcutaneous Opdivo shows promise in kidney cancer

More than 430,000 new cases of renal cell carcinoma are diagnosed globally every year

- PMLiVE

BMS announces CHMP recommendation for multiple myeloma therapy Abecma

More than 50,000 cases of the blood cancer are diagnosed in Europe every year

- PMLiVE

Survey of US oncologists highlights advanced lung cancer research gaps  

Non-small cell lung cancer is responsible for approximately 85% of all lung cancers

- PMLiVE

Roche and Exelis/Ipsen’s drug combination shows promise in phase 3 prostate cancer study

Around 299,000 new cases of prostate cancer will be diagnosed in the US in 2024

- PMLiVE

ACCORD: new guideline to support consistent and complete reporting of consensus methods in biomedical research

Oxford PharmaGenesis has contributed to the development of the new ACCORD reporting guideline to help the medical and scientific communities to improve the reporting of research involving consensus methodologies.

Oxford PharmaGenesis

- PMLiVE

AstraZeneca’s Imfinzi combination shows promise in phase 3 liver cancer study

Hepatocellular carcinoma accounts for about 75% of all primary liver cancers in adults

- PMLiVE

Researchers uncover role of inherited genetic variants in rare blood cancer

There are around 4,000 cases of myeloproliferative neoplasms in the UK each year

- PMLiVE

BMS, Exelixis and Ipsen announce positive four-year results for kidney cancer regimen

More than 430,000 new cases of renal cell carcinoma are diagnosed globally every year

- PMLiVE

Johnson & Johnson’s bladder cancer drug Balversa granted full FDA approval

Urothelial carcinoma accounts for approximately 90% of bladder cancer cases

- PMLiVE

Novartis shares positive phase 3 results for Lutathera in neuroendocrine tumours

The incidence of neuroendocrine tumours has increased over the past several decades

- PMLiVE

BMS presents promising late-stage results for Opdivo plus Yervoy in colorectal cancer

More than 1.9 million cases of colorectal cancer were diagnosed globally in 2020

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links